开发用于评估 CAR T 细胞疗法的生物发光 AML-PDX 小鼠模型的方案。

IF 1.3 Q4 BIOCHEMICAL RESEARCH METHODS

STAR Protocols Pub Date : 2024-12-20 Epub Date: 2024-12-12 DOI:10.1016/j.xpro.2024.103522

Mireia Mayoral Safont, Calum Leitch, Mihaela Popa, May Eriksen Gjerstad, Benjamin Caulier, Else Marit Inderberg, Sébastien Wälchli, Pascal Gelebart, Emmet Mc Cormack

{"title":"开发用于评估 CAR T 细胞疗法的生物发光 AML-PDX 小鼠模型的方案。","authors":"Mireia Mayoral Safont, Calum Leitch, Mihaela Popa, May Eriksen Gjerstad, Benjamin Caulier, Else Marit Inderberg, Sébastien Wälchli, Pascal Gelebart, Emmet Mc Cormack","doi":"10.1016/j.xpro.2024.103522","DOIUrl":null,"url":null,"abstract":"Patient-derived xenograft (PDX) models of acute myeloid leukemia (AML-PDX) offer advantages over cell line models by capturing the complexity and heterogeneity of patient-derived samples. Here, we present a protocol for developing a bioluminescent AML-PDX model in mice to evaluate chimeric antigen receptor (CAR) T cell therapy. We describe steps for transducing, engrafting, expanding, and enriching AML-PDX cells. We then detail procedures for in vitro and in vivo validation of the AML-PDX model for the evaluation of CAR T cell immunotherapy. For complete details on the use and execution of this protocol, please refer to Caulier et al.1.","PeriodicalId":34214,"journal":{"name":"STAR Protocols","volume":"5 4","pages":"103522"},"PeriodicalIF":1.3000,"publicationDate":"2024-12-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11699402/pdf/","citationCount":"0","resultStr":"{\"title\":\"Protocol for the development of a bioluminescent AML-PDX mouse model for the evaluation of CAR T cell therapy.\",\"authors\":\"Mireia Mayoral Safont, Calum Leitch, Mihaela Popa, May Eriksen Gjerstad, Benjamin Caulier, Else Marit Inderberg, Sébastien Wälchli, Pascal Gelebart, Emmet Mc Cormack\",\"doi\":\"10.1016/j.xpro.2024.103522\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Patient-derived xenograft (PDX) models of acute myeloid leukemia (AML-PDX) offer advantages over cell line models by capturing the complexity and heterogeneity of patient-derived samples. Here, we present a protocol for developing a bioluminescent AML-PDX model in mice to evaluate chimeric antigen receptor (CAR) T cell therapy. We describe steps for transducing, engrafting, expanding, and enriching AML-PDX cells. We then detail procedures for in vitro and in vivo validation of the AML-PDX model for the evaluation of CAR T cell immunotherapy. For complete details on the use and execution of this protocol, please refer to Caulier et al.1.\",\"PeriodicalId\":34214,\"journal\":{\"name\":\"STAR Protocols\",\"volume\":\"5 4\",\"pages\":\"103522\"},\"PeriodicalIF\":1.3000,\"publicationDate\":\"2024-12-20\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11699402/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"STAR Protocols\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1016/j.xpro.2024.103522\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/12/12 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q4\",\"JCRName\":\"BIOCHEMICAL RESEARCH METHODS\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"STAR Protocols","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1016/j.xpro.2024.103522","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/12/12 0:00:00","PubModel":"Epub","JCR":"Q4","JCRName":"BIOCHEMICAL RESEARCH METHODS","Score":null,"Total":0}

引用次数: 0

摘要

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Protocol for the development of a bioluminescent AML-PDX mouse model for the evaluation of CAR T cell therapy.

Patient-derived xenograft (PDX) models of acute myeloid leukemia (AML-PDX) offer advantages over cell line models by capturing the complexity and heterogeneity of patient-derived samples. Here, we present a protocol for developing a bioluminescent AML-PDX model in mice to evaluate chimeric antigen receptor (CAR) T cell therapy. We describe steps for transducing, engrafting, expanding, and enriching AML-PDX cells. We then detail procedures for in vitro and in vivo validation of the AML-PDX model for the evaluation of CAR T cell immunotherapy. For complete details on the use and execution of this protocol, please refer to Caulier et al.¹.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊